Science

Publications

Dec 5, 2016
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. ASH 2016. .
View Publication
Dec 5, 2016
Luspatercept
Luspatercept Increases Hemoglobin, Decreases Transfusion Burden, and Improves Patient-Reported Outcomes in Adults with Beta-Thalassemia. ASH 2016. .
View Publication
Dec 4, 2016
Luspatercept
Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Beta-Thalassemia: Preliminary Results From Phase 2 Studies. .
View Publication
Dec 4, 2016
Luspatercept
Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results From Phase 2 Studies. ASH 2016. .
View Publication
Dec 1, 2016
Dalantercept
A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer, a journal of the American Cancer Society. vol. 122 no. 23, .
View Publication
Nov 10, 2016
ACE-083
A Phase 2 study to evaluate ACE-083, a local muscle therapeutic, in patients with FSHD. FSH Society 2016 Research Connect Conference. .
View Publication
Oct 6, 2016
ACE-083
A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. Patient-Centered Charcot-Marie-Tooth Summit. .
View Publication
Sep 9, 2016
ACE-083
A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. 6th International CMTR Consortium Meeting. .
View Publication
Jul 8, 2016
ACE-083
ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases. .
View Publication
Jun 12, 2016
Luspatercept
Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association. .
View Publication
Jun 11, 2016
Luspatercept
Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with Beta-Thalassemia. Congress of the European Hematology Association. .
View Publication
Jun 10, 2016
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low- Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE‐MDS Study. 21st Congress of the European Hematology Association. .
View Publication
Jun 10, 2016
Luspatercept
RAP-536 (Murine Analog of ACE-536/Luspatercept) Inhibits SMAD2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in a Murine Model of Beta-Thalassemia. 21st Congress of the European Hematology Association. .
View Publication
Apr 2, 2016
ACE-083
ACE-083, a Locally-Acting TGF-Beta Superfamily Ligand Trap, Increases Muscle Volume of Targeted Muscle: Preliminary Results from a Phase 1 Dose Escalation Study in Healthy Volunteers. ENDO 2016. .
View Publication
Mar 21, 2016
ACE-083
ACE-083, a locally-acting TGF-beta superfamily ligand trap, increases muscle volume of targeted muscle: Preliminary results from a Phase 1 dose escalation study in healthy volunteers. 2016 MDA Clinical Conference. .
View Publication
Mar 21, 2016
ACE-083
ACE-083, a Locally-Acting TGF-β Superfamily Ligand Trap, Increases Muscle Mass and Strength in a Mouse Model of ALS. 2016 MDA Clinical Conference. .
View Publication
Dec 10, 2015
ACE-083
Phase 1 dose escalation study of ACE-083 in healthy volunteers: Preliminary results for a locally acting muscle therapeutic. The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) Conference. .
View Publication View Additional Publication Info
Dec 7, 2015
Sotatercept
Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. The 57th Annual American Society of Hematology. .
View Publication
Dec 7, 2015
ACE-1332
TGFβ1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis. The 57th Annual American Society of Hematology. .
View Publication
Dec 7, 2015
Luspatercept
RAP-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in Murine β-Thalassemia. The 57th Annual American Society of Hematology. .
View Publication
Dec 7, 2015
Luspatercept
Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. The 57th Annual American Society of Hematology. .
View Publication
Dec 6, 2015
Luspatercept
Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. The 57th Annual American Society of Hematology. .
View Publication
Dec 5, 2015
Luspatercept
Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. The 57th Annual American Society of Hematology. .
View Publication
Nov 6, 2015
Dalantercept
The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium. .
View Publication
Nov 6, 2015
Dalantercept
The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium. .
View Publication
Nov 6, 2015
Sotatercept
Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Subjects: Interim Analysis of a Phase 2 Study. The 48th Annual American Society of Nephrology Kidney Week. .
View Publication
Nov 5, 2015
Sotatercept
Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis. American Society of Nephrology Kidney Week 2015. .
View Publication
Oct 5, 2015
ACE-083
Poster Presentation – A phase 1 dose escalation study of ACE-083, a locally-acting muscle therapeutic, in healthy volunteers. FSHD International Research Consortium. .
View Publication
Oct 1, 2015
ACE-2494
ACE-2494, a Novel GDF Ligand Trap, Increases Muscle Mass Upon Systemic Administration in Mice. 20th International Congress of the World Muscle Society. .
View Publication
Oct 1, 2015
ACE-083
ACE-083 Increases Muscle Hypertrophy and Strength in C57BL/6 Mice. 20th International Congress of the World Muscle Society. .
View Publication
Sep 14, 2015
Sotatercept
Sotatercept (ACE-011) for the Treatment of Chemotherapy-Induced Anemia in Patients with Metastatic Breast Cancer or Advanced or Metastatic Solid Tumors Treated with Platinum-Based Chemotherapeutic Regimens: Results from Two Phase 2 Studies. Supportive Care in Cancer 2015. .
View Publication
Jun 13, 2015
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk MDS: Preliminary Results from the Phase 2 PACE-MDS Study. 20th Congress of the European Hematology Association. .
View Publication
Jun 12, 2015
Luspatercept
Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Liver Iron Concentration in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 20th Congress of the European Hematology Association. .
View Publication
Jun 5, 2015
Dalantercept
Endothelial ALK1 is a Therapeutic Target for Impairing Metastatic Dissemination of Breast Cancer. Cancer Research. vol. 7 no. 12, .
View Publication
Jun 1, 2015
Dalantercept
Poster – The DART Study: Dalantercept Part 1. American Society of Clinical Oncology (ASCO) Annual Meeting. .
View Publication
Jun 1, 2015
Dalantercept
Poster – The DART Study: Dalantercept Part 2. American Society of Clinical Oncology (ASCO) Annual Meeting. .
View Publication
May 30, 2015
Sotatercept
Quantitative Computed Tomography Results for Bone Mass and Abdominal Aortic Vascular Calcification in Hemodialysis Subjects Treated With Escalating Dose Levels of Sotatercept: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress. .
View Publication
May 29, 2015
Sotatercept
The Role of Activin Signaling in the Pathogenesis of Renal Osteodystrophy of CKD-MBD. 52nd ERA-EDTA Congress. .
View Publication
May 29, 2015
Sotatercept
Sotatercept May 29, 2015 Long-term Effects of 3 Dose Levels of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress. .
View Publication
May 2, 2015
Luspatercept
Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study. 13th International Symposium on Myelodysplastic Syndromes (MDS). .
View Publication
Apr 29, 2015
Sotatercept
Oral Presentation – A Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. 13th International Symposium on Myelodysplastic Syndromes (MDS). .
View Publication
Feb 28, 2015
Dalantercept
Poster – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. .
View Publication
Feb 28, 2015
Dalantercept
Oral Presentation – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. .
View Publication
Jan 16, 2015
Dalantercept
The DASH STUDY: A Phase 1b Study of Dalantercept Plus Sorafenib in Advanced Hepatocelluar Carcinoma. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium. .
View Publication
Dec 8, 2014
Luspatercept
Modified ActRIIB-mFc Fusion Protein Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease. 56th Annual American Society of Hematology Annual Meeting and Exposition. .
View Publication
Dec 8, 2014
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results from a Phase 2 Study. 56th Annual American Society of Hematology Annual Meeting and Exposition. .
View Publication
Dec 7, 2014
Sotatercept
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes or Non-Proliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion. 56th American Society of Hematology Annual Meeting and Exposition. .
View Publication
Dec 7, 2014
Luspatercept
Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 56th American Society of Hematology Annual Meeting and Exposition. .
View Publication
Nov 13, 2014
Sotatercept
Sotatercept: Results for Bone Mass and Vascular Calcification in Hemodialysis Subjects Treated With Escalating Doses: Interim Analysis of ACE-011-REN-001. American Society of Nephrology Kidney Week 2014. .